Treatments for PTSD: From Therapy to Ketamine

PTSD treatment has expanded well beyond the “talk about it until it fades” model that dominated for decades. Today, the evidence base spans structured psychotherapies, several classes of medication, brain stimulation, body-oriented approaches, and newer pharmacological agents like ketamine that can reduce symptoms within hours rather than weeks. No single treatment works for everyone, and roughly a third of people who start a first-line therapy either drop out or do not respond adequately, which is why the field keeps pushing into new territory. Understanding what each option actually does, how strong the evidence is, and where the gaps remain can help you make better decisions with your clinician.

Trauma-Focused Talk Therapies

The two therapies with the deepest evidence base are prolonged exposure (PE) and cognitive processing therapy (CPT). Both are structured, time-limited, and specifically designed around trauma rather than general anxiety or depression. PE works primarily through repeated, guided revisiting of the traumatic memory until the emotional charge diminishes. CPT focuses more on identifying and restructuring the distorted beliefs that tend to crystallize after trauma, such as “I’m permanently broken” or “nowhere is safe.” A randomized trial comparing the two found they work through partly different mechanisms: CPT produced greater reductions in hopelessness, and those reductions predicted how much PTSD symptoms improved, while PE’s benefit was more closely tied to the gradual decrease in distress during the exposure exercises themselves.¹

In practice, this means the two therapies feel quite different to the person receiving them. PE involves deliberately recounting the trauma aloud, in detail, session after session, plus real-world exposure to avoided situations. CPT involves more writing and structured worksheets that challenge stuck thinking patterns. Both typically run for about 12 sessions. Your tolerance for direct re-engagement with the trauma memory, and whether your symptoms are driven more by avoidance or by persistent negative beliefs, may steer which one suits you better.

EMDR and the Working Memory Debate

Eye movement desensitization and reprocessing (EMDR) asks you to hold a traumatic memory in mind while following a therapist’s moving finger or another bilateral stimulus back and forth. It sounds unusual, and the mechanism has been debated for years. The leading explanation is that the eye movements tax your working memory, the mental workspace you use to hold and manipulate information in real time. Because your brain can only do so much at once, splitting attention between the memory and the eye-tracking task makes the memory feel less vivid and less emotionally charged.

Lab experiments support this idea. One set of studies found that eye movements slowed reaction times on a secondary task more than auditory beeps did, suggesting eyes place a heavier load on working memory. The same pattern held in a memory experiment: both beeps and eye movements reduced the vividness of negative memories, but eye movements produced larger effects.² A broader review confirmed that recalling traumatic material under a dual-task condition consistently reduces both vividness and emotional intensity compared to recall alone, though at least two studies found the effect did not hold up well at follow-up testing.³ EMDR’s clinical outcomes are broadly comparable to PE and CPT, and it is recommended alongside them in most international guidelines. Some people prefer it because it does not require extended verbal narration of the trauma.

Medications That Are Already Standard

SSRIs remain the first-line medication for PTSD. A Cochrane review pooling data from multiple trials found that SSRIs improved PTSD symptoms in about 58% of participants, compared with 35% on placebo. The trade-off is that people on SSRIs were also more likely to withdraw from treatment due to side effects, though the absolute dropout rate for adverse events was low, around 9%.⁴ Sertraline and paroxetine are the two SSRIs with FDA approval specifically for PTSD, but other SSRIs and the SNRI venlafaxine are used off-label with reasonable supporting evidence.

SSRIs tend to work best on the emotional numbing and avoidance clusters of PTSD. They are less effective at shutting down trauma nightmares, which is where prazosin comes in. Originally a blood pressure medication, prazosin blocks a specific type of norepinephrine receptor in the brain, and norepinephrine surges are heavily implicated in the fight-or-flight activation that drives PTSD nightmares. A placebo-controlled trial in combat veterans found prazosin superior to placebo on recurrent distressing dreams, sleep difficulty, and overall PTSD severity, with improvements across all three symptom clusters.⁵ A broader literature review concluded that prazosin is both effective and safe for trauma-related nightmares.⁶ It is often used alongside an SSRI rather than as a standalone treatment.

Ketamine for PTSD

Ketamine’s appeal for PTSD is speed. Standard treatments take weeks to months to produce noticeable improvement. Ketamine, administered intravenously at sub-anesthetic doses, can begin reducing symptoms within hours. A randomized controlled trial comparing repeated ketamine infusions to midazolam (an active placebo that produces sedation but no antidepressant effect) found that two-thirds of ketamine recipients were treatment responders by week two, compared with one-fifth in the midazolam group. PTSD severity scores dropped nearly 12 points more in the ketamine arm, a large effect size.⁷

The catch is durability. Among ketamine responders in that trial, the median time to losing the response was about four weeks after the infusion course ended. A systematic review and meta-analysis confirmed that ketamine produces statistically significant improvements in PTSD symptom scores by the end of a treatment course spanning one to four weeks, but the evidence on how long those gains last is still thin.⁸ This has led researchers to explore whether combining ketamine with psychotherapy could make the benefits stick.

Animal research offers clues about why ketamine might work at all for trauma-related conditions. In rat models of PTSD, ketamine reversed fear-memory impairment and restored levels of BDNF, a protein crucial for brain plasticity, in the hippocampus and amygdala, two regions consistently implicated in PTSD.⁹ The idea is that ketamine opens a window of enhanced neural plasticity during which traumatic memories might be reprocessed more effectively. One emerging approach, Ketamine Assisted EMDR Therapy, gives a low dose of sublingual ketamine before EMDR sessions, aiming to reduce hyperarousal and improve access to traumatic memories while the brain is in a more flexible state.¹⁰ This combination is still early-stage, but it represents a broader trend of using pharmacology not as a standalone fix but as a catalyst for therapy.

MDMA-Assisted Therapy

MDMA-assisted therapy generated some of the most striking PTSD trial results in recent memory, though its regulatory path has been rocky. In a phase 3 trial, MDMA combined with structured therapy sessions produced a large effect compared to therapy plus placebo, with a between-group effect size around 0.9. Participants received two or three supervised MDMA sessions spaced weeks apart, each followed by integration therapy. MDMA was equally effective in participants with comorbidities often associated with treatment resistance, including the dissociative subtype of PTSD, and outcomes were not modulated by history of alcohol or substance use disorder or severe childhood trauma.¹¹

A second phase 3 trial confirmed the direction of the findings, with about 71% of MDMA-group participants no longer meeting PTSD diagnostic criteria by study end, compared to roughly 48% in the placebo-with-therapy group. About 46% of the MDMA group met full remission criteria, versus about 21% of the placebo group.¹² Beyond symptom scores, MDMA-assisted therapy also produced significantly greater improvements in alexithymia (difficulty identifying and expressing emotions) and self-compassion compared to placebo with therapy.¹³

On the safety side, a systematic review and meta-analysis of the phase 3 data found no significant difference between MDMA and placebo groups in suicidality-related adverse events, cardiac events, or any reported instances of MDMA abuse, misuse, or diversion.¹⁴ Despite these results, the FDA declined to approve MDMA-assisted therapy in 2024, citing concerns about trial methodology and the difficulty of maintaining a true blind when participants can feel whether they received MDMA. The research continues, and the treatment remains unavailable outside clinical trials in the United States.

Brain Stimulation With TMS

Transcranial magnetic stimulation (TMS) uses magnetic pulses delivered through the scalp to alter activity in specific brain regions. For PTSD, the usual target is the dorsolateral prefrontal cortex, a region involved in emotion regulation. High-frequency stimulation of that area is currently rated as a “probable effectiveness” intervention for PTSD.¹⁵ Earlier reviews noted that while high-frequency stimulation outperformed low-frequency in head-to-head comparisons, sample sizes were small and results conflicting.¹⁶

Larger, more recent data is more encouraging. A multisite cohort study comparing three TMS protocols found that all three produced substantial PTSD symptom reductions of 18 to 22 points. Response rates ranged from 63% to 78%, and remission rates hovered around 47% to 49% across protocols.¹⁷ TMS is noninvasive, has a mild side-effect profile (mostly scalp discomfort during sessions), and does not require sedation. It typically involves daily sessions over several weeks, which can be a logistical hurdle.

Stellate Ganglion Block

This is one of the more unexpected entries in the PTSD treatment landscape. A stellate ganglion block (SGB) is an injection of local anesthetic into a cluster of sympathetic nerve cells in the neck. It has been used for decades to treat chronic pain conditions, and its application to PTSD grew out of case reports showing rapid symptom relief, particularly in hyperarousal symptoms like exaggerated startle, hypervigilance, and difficulty sleeping. A meta-analysis of controlled trials found that SGB reduced PTSD severity scores compared to control conditions.¹⁸ Reviews across studies indicate that hyperarousal symptoms tend to benefit most, while re-experiencing symptoms (flashbacks, intrusive memories) respond the least.¹⁹

SGB is not a replacement for therapy or medication. It is best understood as a rapid-acting intervention that can calm the nervous system enough for other treatments to take hold, and it is increasingly being studied as a bridge treatment for people in acute distress.

The Dropout Problem

One of the most underappreciated challenges in PTSD treatment is that a substantial number of people leave therapy before it has a chance to work. In randomized controlled trials, dropout rates tend to look manageable because those trials use carefully screened participants and structured follow-up. But real-world practice tells a different story. A review of the evidence noted that real-world dropout from gold-standard PTSD therapies is substantially higher than what trials report, and that the gap between trial conditions and routine clinical settings is significant.²⁰

In one trial of prolonged exposure with active-duty soldiers, about 41% dropped out before completing 10 sessions, and a virtual reality exposure condition fared no better at 44%.²¹ A naturalistic study in a civilian clinic found a lower but still meaningful dropout rate of about 15%, with younger patients and those living alone at higher risk for quitting early.²² The reasons are varied: some people find the exposure work too distressing in the short term, others face logistical barriers like transportation or childcare, and some simply do not feel a connection with their therapist. This high attrition is a major reason the field keeps looking for alternatives and augmentations.

Body-Oriented and Complementary Approaches

Somatic Experiencing (SE) takes a different angle from the talk-therapy tradition. Rather than working primarily through narrative or cognition, it focuses on physical sensations associated with trauma, like tension, bracing, or the freeze response, and guides the person to discharge those patterns gradually. A randomized controlled trial found large effects on PTSD symptom severity and depression, and about 44% of participants no longer met PTSD diagnostic criteria after treatment, a result that held at follow-up.²³ A scoping review of the broader SE literature found significant symptom reductions across varied settings, trauma types, and session durations.²⁴ The evidence base for SE is smaller than for PE or CPT, but it offers an option for people who struggle with the verbal-narrative demands of those approaches.

Exercise also has a meaningful effect. A network meta-analysis of randomized trials found a dose-response relationship between exercise and PTSD symptom reduction, with the greatest benefits at moderate-to-vigorous intensity, around 30-minute sessions performed more than four times per week. Multicomponent exercise programs (combining aerobic, resistance, and flexibility work) showed the strongest results.²⁵ Exercise is not a substitute for trauma-focused therapy, but it appears to be a genuinely useful adjunct, and unlike most treatments discussed here, it is free, widely accessible, and carries virtually no risk when done sensibly.

Virtual Reality Exposure

Virtual reality exposure therapy (VRET) recreates trauma-related environments, such as combat scenarios or motor vehicle accidents, in a controlled, immersive setting. A systematic review found that VRET was as effective as traditional in-person exposure therapy.²⁶ The technology has a particular advantage for people who have difficulty conjuring vivid imagery on their own, something traditional imaginal exposure relies on heavily. By providing visual, auditory, and sometimes even olfactory cues, VR can activate the traumatic memory more fully, which is actually what you want during an exposure session. A meta-analysis of a graded exposure variant (VR-GET) found a large positive effect compared to control conditions.²⁷ Availability is still the bottleneck: the equipment and software are expensive, and few clinics outside academic centers or military settings have them.

Treating Children and Adolescents

Most of the treatments described above were developed and tested in adults. For children and teenagers, the treatment with the strongest evidence is trauma-focused cognitive behavioral therapy (TF-CBT), which adapts cognitive-behavioral principles for younger populations and, critically, involves the parent or caregiver as an active participant throughout. A meta-analysis found large pre-to-post improvements in PTSD symptoms and showed TF-CBT to be superior to control conditions including waitlist, treatment as usual, and other active treatments.²⁸ Children who received TF-CBT were half as likely to still meet full PTSD criteria at the end of treatment compared to a client-centered comparison, and their parents also showed improvements in depression, parenting ability, and their own trauma-related distress.²⁹

Parental involvement is not just a nice addition. It is a significant factor in how well TF-CBT works. The model has children and parents receiving parallel individual sessions, building skills to recognize and regulate trauma responses before gradually approaching the trauma narrative itself.³⁰ For younger children especially, the caregiver’s own ability to tolerate the child’s distress and support their coping often determines how far the treatment can go.

Can PTSD Be Prevented After a Traumatic Event?

Not everyone who experiences trauma develops PTSD, and there is a growing body of research on whether early intervention can reduce the odds. A randomized trial from the Jerusalem Trauma Outreach and Prevention Study compared several early interventions delivered shortly after traumatic events. At five months, only about 18% to 21% of those who received prolonged exposure or cognitive therapy had developed PTSD, compared to 56% to 62% of those assigned to a waitlist, an SSRI, or placebo.³¹ An evidence review concluded that trauma-focused CBT and modified prolonged exposure, delivered within weeks of a traumatic event to people showing signs of distress, have the strongest prevention evidence. Pharmacologically, hydrocortisone given before high-risk surgery or after severe traumatic injury has shown promise, but most other drugs tried for prevention have not panned out.³²

The practical takeaway is that early psychological debriefing (the kind once common in workplaces after critical incidents) is not the same as structured, trauma-focused therapy. Single-session debriefing has not been shown to prevent PTSD, and some research suggests it may even interfere with natural recovery. What works is targeted, evidence-based therapy for people already showing acute stress symptoms, not a one-size-fits-all group talk immediately after the event.

What Brain Imaging Reveals About Treatment Response

Researchers have started using brain imaging to try to predict who will respond to which treatment. A selective review of MRI studies found that successful psychotherapy response in PTSD involves the ability to dial down amygdala reactivity to trauma-related stimuli, with the anterior cingulate cortex and insula playing key regulatory roles.³³ People whose brains show greater amygdala reactivity and less prefrontal regulation before treatment tend to have a harder time with exposure-based therapies. Brain imaging studies have consistently found that PTSD is associated with increased amygdala function, decreased medial prefrontal and anterior cingulate function, and smaller hippocampal volume.³⁴³⁵

This research is not yet at the point where a clinician can scan your brain and prescribe the right treatment. But it is getting closer. The hope is that biomarkers could eventually guide treatment selection the way genetic testing guides cancer treatment: rather than starting with the most common therapy and switching if it fails, clinicians might be able to match patients to the approach most likely to work for their particular brain pattern from the outset. For now, treatment selection still relies on clinical judgment, patient preference, and a willingness to try something else if the first approach does not take.